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A commentary on
Questioning the HIV-AIDS hypothesis: 30 years of dissent
by Goodson P. Front Public Health (2014) 2:154. doi: 10.3389/fpubh.2014.00154
A recent Opinion article by Dr. Goodson (1) expresses pseudoscientific views typical of HIV/AIDS
denialism (2–13) and ignores the overwhelming evidence that HIV is a causative agent of AIDS, the
evidence accumulated during more than 30 years of research.
Fulfilling the Koch’s Postulate 1: HIV is Invariably
Epidemiologically Associated with AIDS
Dr. Goodson ignores the fact that Koch’s postulates for viruses have been completely fulfilled in the
case of HIV (9, 14, 15).
The overwhelming evidence suggests an invariable epidemiological association of HIV with
AIDS.AIDS occurs exclusively inHIV-infected people (16).HIV can be detected in all AIDS patients
(17). High levels of HIV in the organism predict progression to AIDS (18–23). Many children born
to HIV-infected mothers have developed AIDS and died (24). AIDS-related conditions, such as
Pneumocystis pneumonia and disseminated Mycobacterium avium complex disease, have become
much more common after the start of the HIV epidemic (25). Death rates are much higher in
HIV-seropositive treatment-naïve than in seronegative individuals (26–34).
An HIV-triggered decrease in CD4+ T-lymphocyte count is a specific feature of HIV infec-
tion, and is extraordinarily rare in the absence of HIV (16, 35–37). The HIV-caused CD4+
T-lymphocyte depletion occurs through at least two mechanisms. (1) Direct killing of infected
CD4+ T-lymphocytes. Dr. Goodson seems unfamiliar with the fact that HIV-1, HIV-2, and other
representatives of the genus Lentivirus (e.g., Simian immunodeficiency virus), as well as some other
retroviruses (e.g., Feline leukemia virus and members of the Avian leukosis virus group), exert a
cytopathic effect in infected cells (38). (2) HIV directly kills Th17 CD4+ T-lymphocytes in the
intestinal submucosa, triggering the damage of the mucosal integrity, translocation of microbial
products from the intestine to the blood and chronic immune activation, resulting in furthermassive
loss of CD4+ T-lymphocytes (39, 40).
Dr. Goodson claims that recreational drug use, clotting factor VIII, or receptive anal intercourse,
but not HIV, are causes of AIDS. However, all of these claims have long ago been rejected by
overwhelming scientific evidence (16, 35–37, 41–45).
Fulfilling the Koch’s Postulate 2: HIV has been Isolated from
Patients at all Stages of the Infection
Contrary to Dr. Goodson’s claims, HIV has been isolated from patients at all stages of HIV infection,
including AIDS, and propagated in cell culture (17, 46–54). Various protocols for HIV-1 isolation
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(without “contaminants” claimed by Dr. Goodson) have been
developed, and each of these protocols can be considered “stan-
dard” (55–62). Detailed images of HIV-1 virions, revealing mor-
phology typical of the genus Lentivirus, have been obtained using
transmission electron microscopy (46–48, 53, 63) and electron
cryotomography (64, 65). A combination of immunofluorescent
and electron microscopy has allowed visualization of intracellular
trafficking of individual HIV-1 particles toward the nucleus of
the infected cell (66). The process of cell-to-cell transfer of HIV-
1 between T-lymphocytes has been visualized using high-speed
three-dimensional video microscopy (67).
Fulfilling the Koch’s Postulate 3: Accidental
HIV Transmission in Humans
Dr. Goodson ignores several tragic cases of accidental HIV trans-
mission to laboratory workers who worked with purified HIV-1,
became infected after a needle-stick or mucosal exposure and
developed AIDS-like symptoms. HIV has been isolated from
their blood, and DNA sequencing confirmed that the HIV vari-
ant isolated was identical to the one they were working with
(15, 68–70). Other well-documented cases include HIV trans-
mission from a dentist in the USA to several patients (15, 71),
and HIV transmission through blood transfusion to 11 chil-
dren in the USA (72) and 75 children in the former Soviet
Union (73).
In addition, the Koch’s postulates for HIV and another
lentivirus, Simian immunodeficiency virus, have been fulfilled in
experiments with animal models (15, 74).
HIV Laboratory Testing
Three types of assays are used for HIV detection: (1) ELISA –
specificity 98.5–99.9% (75–77), (2) Western blot (77), and (3)
PCR – specificity 98.3–100% (78–80). The probability that both
ELISA and Western blot would give false-positive results is
extremely low (<1/140,000) (77). Thus, contrary to Dr. Goodson’s
claims, these tests are highly specific for HIV-1. Since the diagno-
sis is based on the combination of the three tests (77), HIV testing
will produce similar conclusions irrespective of the country.
Dr. Goodson misrepresents the study by Rodriguez et al. (81),
which has never stated that PCR “is not sufficiently accurate” (1).
Antiretroviral Therapy
Contrary to Dr. Goodson’s claims, antiretroviral therapy (ART)
has profoundly improved the prognosis for HIV-1-infected
patients, suppressing their viral load, restoring CD4+ T-
lymphocyte count, and reducing the risk of developing AIDS
or dying (Figure 1A) (82–104). The success of ART has been
determined by its high specificity for HIV-1-encoded proteins
(105, 106). Along with therapeutic agents for many other diseases,
FIGURE 1 | Contrasting impacts of HIV/AIDS science versus HIV/AIDS
denialism on public health. (A) Mortality and frequency of use of protease
inhibitor-based combination antiretroviral therapy among HIV-infected patients
with fewer than 100 CD4+ T-lymphocytes per cubic millimeter, in January
1994–June 1997. Reproduced from Ref. (91), with permission from
Massachusetts Medical Society©. (B) Estimating the human costs of Mbeki’s
AIDS policies implemented with the direct support of HIV/AIDS denialists.
Reproduced from Ref. (12), with permission from the Author.
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ART does have side effects, but these are far outweighed by
its benefits (106). New anti-HIV agents should help to mitigate
side effects, overcome drug resistance, and ultimately cure HIV
infection, e.g., through excising HIV proviral DNA from the
chromosome (107–109).
Dr. Goodson misrepresents the study by the ART Cohort Col-
laboration, which showed that ART is extremely beneficial for
HIV-infected patients, but better clinical outcomes are observed
when CD4+ T-lymphocyte counts at the start of ART are higher
than 200 cells/µl (110). These conclusions have been corroborated
by many other studies (111–117) and serve as a background to
recommend starting ART early, when the HIV-triggered damage
of the immune system is easier to restore (106).
Detrimental Impact of HIV/AIDS Denialism
on Public Health
P. Duesberg, D. Rasnick, and some other HIV/AIDS denialists
served on a controversial advisory panel of the South African
president Thabo Mbeki. The policy of the South African govern-
ment over HIV/AIDS during the period 2000–2005 is considered
by a majority of scientists to have resulted in the death of
at least 330,000 HIV-infected people (Figure 1B) (9, 12, 118).
The Opinion article by Dr. Goodson (1) [as well as earlier
published or publicly expressed opinions of P. Duesberg, K.
Mullis, and other denialists, none of whom has ever worked with
HIV/AIDS (2–5, 7–12)] is similarly harmful for public health,
as it disseminates dangerous misinformation about HIV/AIDS
that can affect prevention decisions made by uninfected people
and treatment decisions made by HIV-infected people. There-
fore, the following recommendations should be given to public
health workers: (1) to learn and disseminate up-to-date knowl-
edge on HIV/AIDS based on the most recent scientific liter-
ature, and (2) to be aware of HIV/AIDS denialism and be
able to effectively counteract its detrimental impact on public
health.
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